Overview
Employees
11-50
Mentions in press and media 9
| Date | Title | Description |
| Sign up to see | Sign up to see | Sign up to see |
| Jul 23, 2013 | Программирование: по силам ли каждому? | Anonymous 23 июля 2013, 08:05 Программирование: по силам ли каждому? Оставить комментарий |
| Mar 26, 2013 | After wrapping up Phase 2 trial for schizophrenia drug, Reviva snags $12 million | While approved antipsychotic drugs address the positive symptoms of schizophrenia, like hallucinations and disordered speech, Reviva notes that there are still unmet needs in addressing negative and cognitive symptoms. Some of the FDA-appro... |
| Mar 1, 2013 | Early-stage drug firm Mnemosyne thinks the market is ripe for startups in CNS diseases | So Mnemosyne has made that its job, screening hundreds of compounds with the goal of developing drugs that can modulating those various subtypes to address different neuropsychiatric conditions. It’s starting with NR2B, a subtype that has b... |
| Jul 13, 2011 | Практика, которой нужно следовать: code review | Александр Флахбарт 13 июля 2011, 14:37 Практика, которой нужно следовать: code review Оставить комментарий |
| Nov 23, 2010 | Powerful listening drills for entrepreneurs | The four habits of highly-effective listeners There is a long debate amidst technology entrepreneurs about whether or not, when and how they should listen to customers. The truth is, listening is not a binary activity. Contrary to common be... |
| Aug 16, 2010 | Pepsi spill causes sticky mess in science blogging ecosystem | reader comments 58 with 36 posters participating, including story author Share this story Share on Facebook Share on Twitter Share on Reddit The potential for blogs and other new forms of communication to reshape the media landscape has alm... |
| After wrapping up Phase 2 trial for schizophrenia drug, Reviva snags $12 million | Fresh off completing enrollment in its Phase 2 clinical trial, a California drug startup developing therapies for central nervous system disorders has quietly raised $12 million. Reviva Pharmaceuticals Inc. saw 82 investors pitch in to its ... | |
| Early-stage drug firm Mnemosyne thinks the market is ripe for startups in CNS diseases | Mnemosyne Pharmaceuticals gets its offbeat name from the Greek goddess of memory. It’s fitting because the Providence, Rhode Island startup is hoping to improve memory and cognitive function in patients with neuropsychiatric conditions by m... |